Kasaback-Merritt Syndrome Treated by Transarterial Embolisation of Giant Cavernous Haemangioma

EPY Fung, WH Luk, TK Loke, JCS Chan
Department of Radiology and Organ Imaging, United Christian Hospital, Hong Kong

ABSTRACT
Cavernous haemangiomas of the liver are the most common benign tumours of the liver. With modern imaging modalities, haemangiomas are detected more frequently. This report describes a patient with a giant cavernous haemangioma with consumptive coagulopathy that was successfully treated by transarterial embolisation.

Key Words: Cavernous hemangioma, Embolization, Treatment

INTRODUCTION
Cavernous haemangiomas of the liver are the most common benign tumours of the liver and are found in approximately 2% of liver autopsies. With modern imaging modalities, haemangiomas are detected more frequently. Small haemangiomas are normally clinically silent, and no treatment is needed. However, it is not uncommon for those larger than 4 cm, so called ‘giant’ haemangiomas to be associated with complications. Patients may present with abdominal distension and pain, rupture of the haemangioma with haemoperitoneum, or disorders of coagulation.

CASE REPORT
This report is of a previously healthy 49-year-old women who presented to the United Christian Hospital with insidious onset of a right upper quadrant abdominal mass and pain for 1 year. Physical examination was unremarkable apart from hepatomegaly. Liver function test was normal but she had a low platelet count of 130 x 10^9/L (normal range, 150 to 450 x 10^9/L). Ultrasound scan revealed a 13 cm heterogeneous hyperechoic lesion in the left lobe of the liver (Figure 1). Subsequent computed tomography (CT) scan showed a hypodense mass with peripheral nodular enhancement after contrast administration and gradual centripetal filling on delayed phases. The CT features were typical for a giant haemangioma (Figures 2a and 2b).

Oral analgesia was given to relieve the abdominal pain. However, the right upper abdominal pain became more intense and was not controlled by oral medication. CT scan of the abdomen showed no evidence of tumour rupture or interval change in size. On this occasion, the patient was found to have deranged liver function in addition to the low platelet count. The platelet count dropped from 130 x 10^9/L in May 1999 to 99 x 10^9/L in September 2002, although clinically the patient did not have any bleeding tendency. In view of the consumptive coagulopathy and the increasing abdominal pain,
transarterial embolisation was offered as treatment. Selective embolisation of the supplying branches of the right hepatic artery was performed with PolyVinyL-alcohol (PVA) particles (350 microns). The left hepatic artery was not embolised on the first occasion as the problem of consumption coagulopathy was expected to improve with embolisation of the right hepatic artery (Figure 3).

Follow up CT of the abdomen was done 1 month after the procedure but there was no significant change in size and vascularity of the haemangioma (Figure 4). The platelet count remained low at 103 x 10^9/L. Since the low platelet count did not improve with single right hepatic artery embolisation, a decision was made to embolise both hepatic arteries. Despite the presence of previous PVA particles, there was still significant contrast pooling in the right hepatic artery. On the second procedure (Figure 5), further embolisation was performed, initially using Gelfoam to reduce the blood supply and, subsequently, coil placement in the right hepatic artery, which was completely and permanently occluded (Figure 6). The left hepatic artery was then embolised with Embosphere 500 microns (PVA was not available at that time). The post-embolisation angiogram showed small residual nodular vascularity supplied by the proximal tributaries of the left hepatic artery. No immediate complications were observed. There was no post-embolisation syndrome such as fever or leucocytosis. Only mild abdominal pain was encountered. The platelet count had returned to normal at 151 x 10^9/L at the follow up visit and the abdominal pain was relieved after the procedure. The patient has been asymptomatic for 6 months to date.

**DISCUSSION**

Kasaback-Merritt syndrome is a type of haemorrhagic diathesis due to platelet sequestration by a tumour, and
Transarterial Embolisation of Cavernous Haemangioma

The choice of embolisation agent depends on the initial angiographic appearance and the experience of the radiologists. A preliminary peripheral embolisation for vascular interstices within the haemangioma can be done with gelfoam particles or PVA. Some authors prefer the use of Ivalon as it is a permanent occlusive agent with established biocompatibility. Once the peripheral circulation is occluded, principal arteries can be embolised with steel coils. For patients with arteriovenous or arteriportal shunting, particulate material should not be used to prevent passage into the systemic portal circulation. Postembolisation side effects of fever, pain, and leukocytosis are common. Serious complications are rare and include infection, hepatic abscess, and sepsis; the risk increases with the size of the lesion. While the size of the tumour does not usually change significantly, there is relief of symptoms of abdominal pain and coagulopathy after successful embolisation, which is more important.

In conclusion, this patient underwent successful embolisation of a hepatic haemangioma complicating Kasabach-Merritt syndrome. Transarterial embolisation is an effective therapeutic option for the management of symptomatic haemangioma as an alternative to major surgery.

REFERENCES